IL4 and asthma: Moreover, in the first large pharmacogenetic, placebo-controlled investigation of the IL-4/IL-13 pathway, three doses (1 mg, 3 mg, or 10 mg twice daily for 12 weeks) of inhaled pitrakinra were tested in patients with moderate-to-severe asthma [75].